Novartis (NVS, Financial) has raised its full-year guidance for the third time this year, driven by strong revenue from its key drugs. The Swiss pharmaceutical giant reported that its third-quarter profit and sales surpassed analysts' expectations, prompting the revised forecast.
The company now anticipates a higher end of the 10-20% range for its increase in core operating profit for 2024, compared to its previous expectation of growth in the mid to high range of this spectrum.
Additionally, Novartis expects its full-year sales to achieve a low double-digit percentage increase, an improvement from the prior forecast of high single-digit to low double-digit growth.
